WANBURY
Back to Income Statement
|
WANBURY Last 5 Year Revenue History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Net Sales | ₹600 Cr | ₹578 Cr | ₹500 Cr | ₹511 Cr | ₹393 Cr |
What is the latest Revenue of WANBURY ?
| Year | Revenue |
|---|---|
| Mar2025 | ₹600 Cr |
| Mar2024 | ₹578 Cr |
| Mar2023 | ₹500 Cr |
| Mar2022 | ₹511 Cr |
| Mar2021 | ₹393 Cr |
How is Revenue of WANBURY Trending?
| Years | Revenue | % Change | |
|---|---|---|---|
| Mar2025 | ₹600 Cr | 3.77 | |
| Mar2024 | ₹578 Cr | 15.63 | |
| Mar2023 | ₹500 Cr | -2.26 | |
| Mar2022 | ₹511 Cr | 30.23 | |
| Mar2021 | ₹393 Cr | - | |
Compare Revenue of peers of WANBURY
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| WANBURY | ₹1,090.6 Cr | -5.5% | 10.8% | 22.3% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹474,396.0 Cr | 1.8% | 5.6% | 16.7% | Stock Analytics | |
| DIVIS LABORATORIES | ₹196,990.0 Cr | 0.5% | 13.1% | 10.9% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹186,354.0 Cr | -2.7% | 5.1% | 42.4% | Stock Analytics | |
| CIPLA | ₹116,705.0 Cr | 2.1% | -0.6% | -4.5% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹94,790.0 Cr | -4% | -17.5% | -8.6% | Stock Analytics | |
WANBURY Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| WANBURY | -5.5% |
10.8% |
22.3% |
| SENSEX | -0.9% |
-0.4% |
-6.1% |
You may also like the below Video Courses